Long-Term Data Support BCT for BRCA-Mutated Breast Cancer
-
By
May 16, 2025
-
2 min
Researchers from South Korea investigated the long-term oncologic outcomes of breast-conserving treatment (BCT) compared with mastectomy in patients with breast cancer carrying BRCA1 or BRCA2 pathogenic variants. The study included 575 South Korean female patients with a median follow-up of 8.3 years. The results, published in JAMA Network Open, indicated that there were no significant differences in oncologic outcomes between the BCT and mastectomy groups, suggesting that BCT is a safe and effective surgical option for these patients, offering comparable long-term oncologic outcomes to mastectomy.
1. South Korean study investigated oncologic outcomes of BCT vs. mastectomy in breast cancer patients with BRCA1 or BRCA2 pathogenic variants. 2. Included 575 female patients with a median follow-up of 8.3 years. 3. No significant differences in oncologic outcomes between BCT and mastectomy groups. 4. BCT considered a safe and effective option, offering comparable long-term outcomes to mastectomy. 5. Further prospective studies recommended for confirmation of findings.
Listen Tab content
